Viewing Study NCT03534804


Ignite Creation Date: 2025-12-24 @ 9:14 PM
Ignite Modification Date: 2025-12-25 @ 7:03 PM
Study NCT ID: NCT03534804
Status: COMPLETED
Last Update Posted: 2024-11-26
First Post: 2018-05-11
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Sponsor: University of Utah
Organization: